Kris has a PhD in Medical Sciences from Hasselt University and holds a Masters degree in chemistry from Ghent University. Kris has over 20 years of experience in the life sciences and financial sector. He started his scientific career as a Postdoctoral fellow at the Longwood Medical Research Center, Harvard Medical School and Head of oncology research at Hasselt University. Kris gained industry experience as patent and licensing manager at Johnson & Johnson and expanded his expertise in the financial sector as equity analyst and fund manager for Puilaetco Bankers.

As an independent corporate development advisor he held several advisory, management and director mandates in private and public biomedical companies including Beta-Cell, Apitope, SEPS Pharma, TiGenix, Laboratoria Smeets and Promethera.

He has also been acting as sector specialist for a number of investment boutiques and venture capital firms such as Puilaetco Bankers, Bryan Garnier, Kepler Equities, LRM and Oyster Venture Partners, where he was involved in the identification, execution and follow-up of private and public financing transactions.

Yanick Fanton graduated in 2012 with a master’s degree in clinical and molecular sciences and obtained a PhD on human cardiac stem cells for the treatment of myocardial infarction. She completed additional education in strategy, business HR and marketing via a business management post-graduate. Stem cells and cell therapy development have been a central part of both her education and her first career experiences.

Yanick joined Beta-Cell NV in 2016, a bio-tech company that is developing a cell therapy for the treatment of diabetes. She started as a scientist and switched to R&D director in 2019. As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.

After studying Business Administration and Logistics Management, Robbert started his career as a process controller in the irradiation industry. Moving to the life science industry in 2004, Robbert initially worked for Harlan Laboratories and Envigo, where he held various positions. From 2017 onwards he was Manager of Operations responsible for the European production sites of research models. In April 2021 he joined the InnoSer team as COO. His special interest lies in the field of people-oriented management, collaboration, and setting up structured and efficient work processes. His ultimate goal is to make a difference for our customers.

Maarten obtained his Master’s degree in Bioprocess Engineering at Wageningen University and a PhD degree in behavioural and molecular Neuroscience at the VU University Amsterdam. Hereafter he joined the company Sylics. As CSO, Maarten directed Sylics’ R&D team in the establishment of mouse models of CNS diseases and a suite of bioinformatics services, including cloud-based AHCODA^TM data analyses. He authored on >60 peer reviewed publications, and has a broad network in academia and pharma/biotech industry. In 2018 Maarten became the CEO of the Sylics, until its merge with InnoSer laboratories in 2023. Maarten contributes more than 15 years of experience in high quality preclinical in vivo neuroscience studies.

Amandine holds a PhD in molecular biology and a master’s degree in biochemistry and molecular biology from the University of Liège. She has built strong expertise across several fields, including oncology, angiogenesis, RNA interference, and extracellular vesicles. To complement her scientific background, she also completed a management and business administration program. Amandine joined InnoSer in 2022 and currently serves as Director of Business Development and Oncology. She is responsible for market strategy and development and advises customers on the design of preclinical studies.

Roeland holds a master’s degree in Accounting from the Katholieke Universiteit Leuven. He started his career as a consultant in an accountancy firm, where he supported companies in all stages of growth — from drafting business plans for start-ups to guiding scale-ups in securing funding and preparing businesses for acquisition. His expertise includes financial reporting, budgeting, cash flow management, and strategic planning. Roeland has been working with InnoSer since the establishment of the Belgian branch in 2017 as a financial advisor. In 2024, he joined InnoSer full-time as Director of Finance and Administration. In this role, he is responsible for financial management, compliance, process optimization, and supporting the company’s strategic development through sound financial operations. Roeland coordinates the internal support team, ensuring smooth administrative and financial processes across the organization.